Lilly insulin prices come under microscope
Over the past 20 years, while the price of a gallon of milk climbed 23 percent and the sticker on a Dodge Caravan minivan rose 21 percent, the list price of the insulin Humalog shot up 1,157 percent.
Pharmaceutical
Articles
Trump lashes out after Merck exec resigns from president’s council
President Donald Trump criticized drug prices immediately after Merck & Co.’s CEO quit the president’s council of manufacturing executives Monday, to take a “stand against intolerance and extremism.”
Lilly, other drug giants hunt for patients in India’s remote corners
Global pharmaceutical companies including Indianapolis-based Eli Lilly and Co. are heading into smaller cities and rural areas to learn about the health care needs of about 70 percent of India’s population.
Lilly to pay up to $400M to buy rights for early-stage immune drug
The deal is Eli Lilly and Co.’s latest push into a growing disease area for such disorders as arthritis, lupus and multiple sclerosis.
Drugmakers aren’t sweating next wave of patent losses
Drugmakers like Eli Lilly and Co. plunged off a patent cliff earlier this decade, losing billions in sales as lucrative branded drugs lost exclusivity. An expensive lobbying effort aimed at preventing a repeat is paying off.
British Supreme Court rules in Eli Lilly’s favor in drug dispute
Britain's Supreme Court has ruled in favor of Eli Lilly and Co. in a patent dispute with generic drugmaker Actavis over Lilly's Alimta cancer treatment.
Indiana adding opioid treatment programs at five sites
The new sites are located at health centers in Johnson, Allen, Vigo, Monroe and Tippecanoe counties, the Indiana Family and Social Services Administration announced Wednesday morning.
Pharmakon collected $560K in incentives before ceasing operations
Noblesville-based Pharmakon had a history of making state and local incentive agreements before suspending operations last year after a Food and Drug Administration investigation uncovered safety issues and possible criminal activity.
Pharmacy boss blamed for meningitis outbreak gets 9 years
The co-owner of a pharmacy responsible for the deaths of 76 people was sentenced Monday to nine years in prison. Indiana was one of the state hit hardest by the 2012 nationwide fungal meningitis outbreak.
Performance gap widening in some generic drugs, researchers say
As medicines—especially those that treat conditions such as anxiety or depression—are becoming more complex, it’s not just the mix of active ingredients that generic drugmakers have to replicate. It’s also the release mechanism.
Indiana crackdown on opioids sparks more pharmacy robberies
While making opioid prescriptions harder to get, Indiana’s crackdown helped spur a twofold increase in robberies of pharmacies that exacerbated the state’s standing as No. 1 in the nation for those crimes.
Lilly, Pfizer get boost for non-opioid pain drug
The companies say the drug, now in late-stage clinical trials, could be more effective for pain treatment than opioids—a dangerous category of pain killers that includes hydrocodone, morphine and fentanyl—without the abuse potential of such medications.
Pharmakon owner, compliance director face criminal charges
The owner and the director of compliance for Noblesville-based Pharmakon Pharmaceuticals Inc. have been charged with multiple criminal counts related to the sale of over-potent compounded painkillers that sickened at least three infants.
Nevada forces drugmakers to reveal insulin pricing, profits
America's three insulin manufacturers—Indianapolis-based Eli Lilly and Co., Sanofi and Novo Nordisk—would face fines of $5,000 daily if they fail to provide the data.
Drugmaker cashing in on opioid epidemic, one state law at a time
In statehouses across the country and in Congress, drugmaker Alkermes is pushing its own addiction treatment while contributing to misconceptions and stigma about other medications used to treat opioid addiction.
High court ruling speeds up generic biotech drug approval
The court's unanimous ruling Monday means a loss of billions in sales to makers of original versions of biologic drugs.
FDA asks drugmaker to stop selling its opioid painkiller
Besides contributing to overdoses, abuse of Opana ER was blamed for a 2015 outbreak of HIV and hepatitis C in southern Indiana linked to sharing needles, according to the FDA.
First bellwether trial for ‘low-T’ treatment could have ramifications for Lilly
A set of consolidated lawsuits accuse AbbVie and other makers of testosterone-replacement medicines, including Eli Lilly and Co., of hiding or downplaying their products’ risk for blood clots or other serious injuries.
Drugmakers brace for Trump proposals to tackle U.S. prices
Top pharmaceutical CEOs say they expect President Donald Trump, a frequent critic of industry pricing practices, to take steps soon to address high U.S. drug costs.
Lilly Endowment assets ebb in 2016 as it grants $452.8M
After several years in which the value of its assets swelled, philanthropic giant Lilly Endowment Inc. watched its coffers shrink 12.7 percent in 2016 from about $11.8 billion to $10.3 billion.